Artiva Biotherapeutics Raises $300M in Common Stock and Warrants Offering
Event summary
- Artiva Biotherapeutics priced a $300M offering of 23.87M shares of common stock at $11.52 per share and pre-funded warrants for 2.17M shares at $11.5199 per share.
- The offering is expected to close on May 11, 2026, subject to customary closing conditions.
- Key investors include Caligan Partners, Venrock Healthcare Capital Partners, and Blackstone Multi-Asset Investing.
- Joint book-running managers are Jefferies, TD Cowen, and Cantor, with Wedbush PacGrow and Needham & Company as co-lead managers.
- Proceeds will be used to advance Artiva's lead program, AlloNK®, a non-genetically modified NK cell therapy for autoimmune diseases.
The big picture
Artiva Biotherapeutics' $300M offering underscores the growing investor interest in cell therapies targeting autoimmune diseases. The funding will be critical as Artiva advances its lead program, AlloNK®, into pivotal trials, positioning the company to compete with established players in the space. The participation of major investment firms highlights the strategic importance of Artiva's technology in a market increasingly focused on innovative treatments for debilitating conditions.
What we're watching
- Clinical Progress
- How the $300M infusion will accelerate Artiva's Phase 3 trial for refractory rheumatoid arthritis in 2026.
- Market Positioning
- Whether Artiva can sustain its lead in the competitive landscape of cell therapies for autoimmune diseases.
- Investor Confidence
- The pace at which key investors like Blackstone and Venrock Healthcare Capital will continue to support Artiva's growth.
Related topics